Centessa Pharmaceuticals plc
NASDAQ:CNTABiotechnology
-$0.07 today
- Market cap
- $6.27B
- Beta
- 1.12
- P/E (TTM)
- -24.4
- EPS (TTM)
- -$1.63
Volume 0.00M
Average 2.63M
CNTA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Centessa Pharmaceuticals plcNASDAQ: CNTA
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $10.57M rose 34.0% year over year, ahead of the +1.1% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 33.1% from the prior quarter. Over 3 fiscal years it compounded at +7.4% a year.
Context
- Stock-based compensation amounted to 206.4% of revenue in FY2025.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +34.0% holds above the trailing-twelve-month pace of +1.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 30.96M USD
- Year-over-year change
- -7.7%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.96M | -7.7% |
| FY2024 | 2024-12-31 | 33.55M | +14.1% |
| FY2023 | 2023-12-31 | 29.39M | +17.7% |
| FY2022 | 2022-12-31 | 24.97M | — |
| FY2021 | 2021-12-31 | 0 | — |
Stock-Based Compensation vs competitors
How CNTA compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +1.1% is the 5th highest of 10, against a peer median of -0.2%.
- Over three fiscal years its annual growth of +7.4% compares with a peer median of +41.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $142.83M USD | -11.3% | +5.5% | 21.3% | |
| LTM Sep 2026 | $64.29M USD | +20.9% | +38.1% | — | |
| LTM Jun 2026 | $58.29M USD | -12.7% | +2.3% | 13.0% | |
| LTM Jun 2026 | $57.63M USD | +60.4% | +178.5% | — | |
| LTM Jun 2026 | $39.28M USD | -8.1% | +44.6% | — | |
| LTM Sep 2026 | $36.45M USD | +48.9% | +240.5% | 591.2% | |
| LTM Mar 2026 | $33.64M USD | +1.1% | +7.4% | — | |
| LTM Jun 2026 | $28.46M USD | +203.0% | +66.4% | — | |
AAPGAscentage Pharma Group International | FY2025 | CN¥20.87M CNY | -0.2% | -1.9% | 3.7% |
| LTM Sep 2026 | $7.7M USD | -87.8% | — | 0.6% | |
| Peer median (excluding CNTA) | — | -0.2% | +41.3% | 13.0% | |
Competitors are the stored peer set for CNTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (381.85M) | (216.21M) | (151.09M) | (235.76M) | (197.53M) |
| Depreciation & Amortization | 34K | 131K | 810K | 942K | 921K |
| Deferred Income Tax | 0 | (2.86M) | (26.53M) | 2.65M | 2.51M |
| Stock-Based Compensation | 0 | 24.97M | 29.39M | 33.55M | 30.96M |
| Change in Working Capital | (5.38M) | (2.83M) | (18.86M) | 22.1M | (51.24M) |
| Accounts Receivables | (6.72M) | (11.71M) | (12.09M) | (6.6M) | 2.91M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 6.35M | (2.72M) | (4.59M) | 2.96M |
| Other Working Capital | 1.34M | 2.53M | (4.04M) | 33.29M | (57.11M) |
| Other Non-Cash Items | 251.06M | (3.75M) | 5.93M | 34.46M | 20.56M |
| Operating Cash Flow | (136.14M) | (200.55M) | (160.34M) | (142.06M) | (193.82M) |
| Capital Expenditures | (185.98K) | (1.14M) | (169K) | (34K) | (371K) |
| Acquisitions (Net) | 63.43M | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (264.91M) | (140.53M) | (739.76M) |
| Sales of Investments | 0 | 0 | 138.08M | 171.83M | 321.6M |
| Other Investing Activities | 0 | 206K | 0 | 0 | 0 |
| Investing Cash Flow | 63.25M | (931K) | (127M) | 31.27M | (418.53M) |
| Debt Repayment | 73.64M | 0 | 0 | (762K) | 0 |
| Common Stock Issued | 586.44M | 718K | 20.81M | 359.61M | 296.72M |
| Common Stock Repurchased | (12K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (261K) | 310K | 5.91M | (5.19M) |
| Financing Cash Flow | 660.07M | 457K | 21.12M | 364.75M | 291.53M |
| Effect of Forex Changes | 2.9M | (418K) | 615K | 1.23M | (448K) |
| Net Change in Cash | 590.08M | (201.44M) | (265.61M) | 255.19M | (321.27M) |
| Free Cash Flow | (136.33M) | (201.68M) | (160.51M) | (142.09M) | (194.19M) |
Centessa Pharmaceuticals plc
NASDAQ:CNTA
Intrinsic Alpha fair value
Locked
Current Price
$40.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.